Literature DB >> 21839019

An additional line of therapy with pegylated interferon and ribavirin after rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia and indolent non-Hodgkin's lymphoma previously treated with interferon.

Endri Mauro1, Mariangela Pedata, Anna Ermacora, Cesare Mazzaro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21839019      PMCID： PMC3258996          DOI： 10.2450/2011.0006-11

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  11 in total

1.  Rituximab for the treatment of type II mixed cryoglobulinemia.

Authors:  F Zaja; D Russo; G Fuga; F Patriarca; A Ermacora; M Baccarani
Journal:  Haematologica       Date:  1999-12       Impact factor: 9.941

2.  Interferon and ribavirin combination therapy in patients with chronic hepatitis C and mixed cryoglobulinemia.

Authors:  C Donada; A Crucitti; V Donadon; L Chemello; A Alberti
Journal:  Blood       Date:  1998-10-15       Impact factor: 22.113

3.  Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia.

Authors:  David Saadoun; Mathieu Resche Rigon; Damien Sene; Benjamin Terrier; Alexandre Karras; Laurent Perard; Yoland Schoindre; Brigitte Coppéré; François Blanc; Lucile Musset; Jean-Charles Piette; Michele Rosenzwajg; Patrice Cacoub
Journal:  Blood       Date:  2010-05-03       Impact factor: 22.113

4.  Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease.

Authors:  Antonio Petrarca; Luigi Rigacci; Patrizio Caini; Stefano Colagrande; Paolo Romagnoli; Francesco Vizzutti; Umberto Arena; Carlo Giannini; Monica Monti; Paolo Montalto; Marco Matucci-Cerinic; Alberto Bosi; Giacomo Laffi; Anna Linda Zignego
Journal:  Blood       Date:  2010-03-22       Impact factor: 22.113

5.  Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study.

Authors:  Franco Dammacco; Felicia Anna Tucci; Gianfranco Lauletta; Pietro Gatti; Valli De Re; Vincenza Conteduca; Silvia Sansonno; Sabino Russi; Maria Addolorata Mariggiò; Maria Chironna; Domenico Sansonno
Journal:  Blood       Date:  2010-03-22       Impact factor: 22.113

6.  Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study.

Authors:  David Saadoun; Mathieu Resche-Rigon; Vincent Thibault; Jean-Charles Piette; Patrice Cacoub
Journal:  Arthritis Rheum       Date:  2006-11

Review 7.  Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis.

Authors:  David Saadoun; Aurelien Delluc; Jean Charles Piette; Patrice Cacoub
Journal:  Curr Opin Rheumatol       Date:  2008-01       Impact factor: 5.006

8.  Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients.

Authors:  Benjamin Terrier; David Saadoun; Damien Sène; Jérémie Sellam; Laurent Pérard; Brigitte Coppéré; Alexandre Karras; François Blanc; Matthias Buchler; Emmanuelle Plaisier; Pascale Ghillani; Michelle Rosenzwajg; Patrice Cacoub
Journal:  Arthritis Rheum       Date:  2009-08

9.  Efficacy and safety of rituximab in type II mixed cryoglobulinemia.

Authors:  Francesco Zaja; Salvatore De Vita; Cesare Mazzaro; Stefania Sacco; Daniela Damiani; Ginevra De Marchi; Angela Michelutti; Michele Baccarani; Renato Fanin; Gianfranco Ferraccioli
Journal:  Blood       Date:  2003-01-30       Impact factor: 22.113

10.  Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis.

Authors:  P Lamprecht; C Lerin-Lozano; H Merz; R H Dennin; A Gause; J Voswinkel; S O Peters; O Gutzeit; A C Arlt; W Solbach; W L Gross
Journal:  Ann Rheum Dis       Date:  2003-12       Impact factor: 19.103
View more
  5 in total

Review 1.  Non-Hodgkin lymphoma and hepatitis C: where we are and what next?

Authors:  Mihály Sulyok; Mihály Makara; Eszter Újhelyi; István Vályi-Nagy
Journal:  Pathol Oncol Res       Date:  2014-10-02       Impact factor: 3.201

Review 2.  Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy.

Authors:  Luca Arcaini; Michele Merli; Stefano Volpetti; Sara Rattotti; Manuel Gotti; Francesco Zaja
Journal:  Clin Dev Immunol       Date:  2012-08-26

3.  Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy.

Authors:  Teresa Urraro; Laura Gragnani; Alessia Piluso; Alessio Fabbrizzi; Monica Monti; Elisa Fognani; Barbara Boldrini; Jessica Ranieri; Anna Linda Zignego
Journal:  Case Reports Immunol       Date:  2015-03-01

Review 4.  Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma.

Authors:  Michele Merli; Giuseppe Carli; Luca Arcaini; Carlo Visco
Journal:  World J Gastroenterol       Date:  2016-10-14       Impact factor: 5.742

Review 5.  The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents.

Authors:  Dario Roccatello; Savino Sciascia; Daniela Rossi; Laura Solfietti; Roberta Fenoglio; Elisa Menegatti; Simone Baldovino
Journal:  Oncotarget       Date:  2017-06-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.